XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 28, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 43,074 $ 36,964
Accounts receivable, net 121,925 122,789
Inventory 90,032 91,333
Prepaid and other current assets 16,923 16,913
Assets held for sale 26,734 0
Total current assets 298,688 267,999
Property and equipment, net 29,425 36,605
Goodwill 7,462 7,462
Intangible assets, net 414,809 482,350
Operating lease assets 9,779 13,353
Deferred tax assets 7,396 0
Investment and other assets 1,933 3,141
Total assets 769,492 810,910
Current liabilities:    
Accounts payable 16,849 23,038
Accrued liabilities 128,697 119,795
Current portion of long-term debt 38,566 27,848
Current portion of contingent consideration 19,228 0
Other current liabilities 3,918 4,816
Liabilities held for sale 4,234 0
Total current liabilities 211,492 175,497
Long-term debt, less current portion 345,021 366,998
Deferred income taxes 0 1,213
Contingent consideration 0 18,150
Other long-term liabilities 26,146 27,934
Total liabilities 582,659 589,792
Commitments and contingencies (Note 11)
Stockholders’ Equity    
Additional paid-in capital 503,134 494,254
Accumulated deficit (354,922) (321,536)
Accumulated other comprehensive income 445 794
Total stockholders’ equity attributable to Bioventus Inc. 148,738 173,591
Noncontrolling interest 38,095 47,527
Total stockholders’ equity 186,833 221,118
Total liabilities and stockholders’ equity 769,492 810,910
Common Class A    
Stockholders’ Equity    
Common stock, value 65 63
Common Class B    
Stockholders’ Equity    
Common stock, value $ 16 $ 16